Hm Payson & CO Bei Gene, Ltd. Transaction History
Hm Payson & CO
- $6.76 Billion
- Q3 2025
A detailed history of Hm Payson & CO transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Hm Payson & CO holds 2 shares of BGNE stock, worth $453. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2Holding current value
$453% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding BGNE
# of Institutions
291Shares Held
32.1MCall Options Held
113KPut Options Held
106K-
Baker Bros. Advisors LP New York, NY8.8MShares$1.99 Billion20.22% of portfolio
-
Primecap Management CO Pasadena, CA5.09MShares$1.15 Billion0.94% of portfolio
-
Capital International Investors Los Angeles, CA4.89MShares$1.11 Billion0.2% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E91.03MShares$234 Million9.68% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.02MShares$231 Million0.03% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $23.5B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...